Company: SXTPW
Filing Date: 2025-01-30
Form Type: 424B5
Source: 0001213900-25-008098
Chunk: 10

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-01-30
Form: 424B5
Chunk 10
---
 for which there are few available treatments.15                
 Since it has broad-spectrum activity against drug-resistant Candida spp in culture, Tafenoquine, has the potential to        
 be a market leading therapy for treatment/prevention of C. auris, and to be added to the standard of care regimens for other 
 Candida infections.16                                                                                                        |

| 10 | This estimate is based                                                                                                                  
 on the observations of Krugeler et al (Emerg Infect Dis 2021;27:616-61) who reported that 476,000 cases of Lyme disease occur           
 in U.S. states where babesiosis is endemic and Krause et. al. (JAMA 1996;275:1657-16602) who reported that 10% of Lyme disease patients 
 are co-infected with babesiosis and that according to Krause et al (AJTMH 2003;6:431-436) fact that about 80% of cases are symptomatic  
 (thus 476,000*10%*80% = 38,000 cases of babesiosis per year).                                                                           |

| 11 | Bloch                                           
 et al Open Forum Infect Dis 2022;9(11):ofac597. |

| 12 | According           
 to IDSA guidelines. |

| 13 | See Krause et al Clin Infect Dis 2024; doi:10.1093/cid/ciae238 and https://ysph.yale.edu/news-article/antimalarial-drug-is-effective-against-tick-borne-infection-babesiosis/. |

| 14 | Marx                           
 et. al., MMWR 2021;70:612-616. |

| 15 | https://www.cdc.gov/fungal/diseases/candidiasis/invasive/statistics.html.; https://www.cdc.gov/fungal/candida-auris/tracking-c-auris.html. |

| 16 | Dow                                             
 and Smith New Microb New Infect 2022;45:100964. |

<div align='center'>S-3</div>

| ● | Prevention of fungal                                                                                                                          
 pneumonias. There are up to ~ 91-92,000 new patient cases each year in the United States for which antifungal prophylaxis is                  
 recommended, including acute lymphoblastic leukemia (up to 6,540 cases) and large B-cell lymphoma (up to 18,000 cases) patients receiving